Jenburkt Pharmaceuticals Limited
Counter Cyclical raised its stake in Jenburkt Pharmaceuticals from 4.99% to 5.01% by purchasing 326 shares through the open market, crossing the 5% disclosure threshold.
A pharmaceutical manufacturer established in 1985, Jenburkt Pharma produces and distributes branded medications and healthcare products across India's medical sector. The company operates across multiple therapeutic areas, serving hospitals, clinics, and retail pharmacies through an established distribution network. Jenburkt focuses on delivering accessible and affordable healthcare solutions to patients throughout the domestic market through its diverse product portfolio.
Founded in 2019, managing around Rs 712 cr in a deep-value smallcap strategy. Run by Gurmit Singh Narang (MA Economics, Delhi School of Economics) with a zero-management-fee structure: 20 percent performance share over a 10 percent hurdle. Concentrated bets on out-of-favour smallcaps.
